KPTIKaryopharm Therapeutics Inc.

KPTI Stock Price, Valuation & Chart | Karyopharm Therapeutics Inc.

Compare

$1.790-0.06 (-3.24%)

At close · 02 Sept 2026, 08:00 pm

Sector: Healthcare Industry: Biotechnology KPTI intrinsic value KPTI calculated fair value vs price

Overview Financials Dividends Ratios

KPTI Historical price chart

KPTI Key Stats

Fair Value

Disclaimer

Disclaimer: This fair value estimate is for informational purposes only and should not be considered as investment advice. Fair value calculations are based on DCF (Discounted Cash Flow), P/E Multiple, and P/S Multiple models and assumptions that may not reflect actual market conditions. Always conduct your own research and consult with a financial advisor before making investment decisions.

Unlock

Market Capitalization40.57M

PE Ratio-0.14

EPS-13.06

Trading Volume1.29M

Today's High/Low1.94/1.73

Dividend Yield0.00

52 Week High/Low10.99/1.73

Shares Outstanding22.66M

KPTI Financial Statement

KPTI Analyst ratings

KPTI Analysis & performance metrics

KPTI Company profile

Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of…

Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases. The company discovers, develops, and commercializes novel and Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1.…

KPTI Management team

Name

Position

Kristin Abate

Vice President, Chief Accounting Officer & Assistant Treasurer

Mansoor Raza Mirza M.D.CTO

Clinical Consultant, Member of Scientific Advisory Board & Independent Director

James Accumanno J.D.

Chief Compliance Officer

Reshma Rangwala M.D., Ph.D.

Executive Vice President, Chief Medical Officer & Head of Research

Sohanya Cheng M.B.A.

Executive Vice President, Chief Commercial Officer & Head of Business Development

Sharon Shacham M.B.A., Ph.D.

Co-Founder & Chairman of Scientific Advisory Board

Lori A. Macomber CPACFO

EVice President, Chief Financial Officer & Treasurer

Brendan Twohig Strong

SVice President of Investor Relations & Corporate Communications

Name

Position

Kristin Abate

Vice President, Chief Accounting Officer & Assistant Treasurer

Mansoor Raza Mirza M.D.CTO

Clinical Consultant, Member of Scientific Advisory Board & Independent Director

James Accumanno J.D.

Chief Compliance Officer

Reshma Rangwala M.D., Ph.D.

Executive Vice President, Chief Medical Officer & Head of Research

Sohanya Cheng M.B.A.

Executive Vice President, Chief Commercial Officer & Head of Business Development

Sharon Shacham M.B.A., Ph.D.

Co-Founder & Chairman of Scientific Advisory Board

Lori A. Macomber CPACFO

EVice President, Chief Financial Officer & Treasurer

Brendan Twohig Strong

SVice President of Investor Relations & Corporate Communications

Management Team

Kristin Abate

Vice President, Chief Accounting Officer & Assistant Treasurer

Mansoor Raza Mirza M.D.CTO

Clinical Consultant, Member of Scientific Advisory Board & Independent Director

James Accumanno J.D.

Chief Compliance Officer

Reshma Rangwala M.D., Ph.D.

Executive Vice President, Chief Medical Officer & Head of Research

Sohanya Cheng M.B.A.

Executive Vice President, Chief Commercial Officer & Head of Business Development

Sharon Shacham M.B.A., Ph.D.

Co-Founder & Chairman of Scientific Advisory Board

Lori A. Macomber CPACFO

EVice President, Chief Financial Officer & Treasurer

Brendan Twohig Strong

SVice President of Investor Relations & Corporate Communications

Management

Kristin Abate

Vice President, Chief Accounting Officer & Assistant Treasurer

Mansoor Raza Mirza M.D.CTO

Clinical Consultant, Member of Scientific Advisory Board & Independent Director

James Accumanno J.D.

Chief Compliance Officer

Reshma Rangwala M.D., Ph.D.

Executive Vice President, Chief Medical Officer & Head of Research

Sohanya Cheng M.B.A.

Executive Vice President, Chief Commercial Officer & Head of Business Development

Sharon Shacham M.B.A., Ph.D.

Co-Founder & Chairman of Scientific Advisory Board

Lori A. Macomber CPACFO

EVice President, Chief Financial Officer & Treasurer

Brendan Twohig Strong

SVice President of Investor Relations & Corporate Communications

Total 8 executives

KPTI Frequently asked questions

What is Karyopharm Therapeutics Inc. (KPTI) Stock Price?

Current stock price of Karyopharm Therapeutics Inc. (KPTI) stock is $1.790. The stock price is -3.24% lower in the session. The intraday range can be seen from this page. Volume of Karyopharm Therapeutics Inc. (KPTI) stock is 1.29M.

Last updated at 02 Sept 2026, 08:00 pm.

Why is the Karyopharm Therapeutics Inc. (KPTI) stock price going up or down today?

The stock price of Karyopharm Therapeutics Inc. (KPTI) can change with earnings, company news, and overall market sentiment. Karyopharm Therapeutics Inc. operates in the Healthcare / Biotechnology market, so sector-wide moves can also affect the share price. Use the live price, percentage change, and volume on this page to judge whether a move looks meaningful.

Is the Karyopharm Therapeutics Inc. stock expensive at its current price?

Whether Karyopharm Therapeutics Inc. looks expensive depends on valuation metrics versus its growth outlook. The P/E ratio shown for KPTI on this page is -0.14. EPS on this page is -13.06. Compare those figures with peers and growth expectations before deciding if the current Karyopharm Therapeutics Inc. price is justified.

How has the stock price of Karyopharm Therapeutics Inc. (KPTI) performed historically?

Historical performance for Karyopharm Therapeutics Inc. (KPTI) is shown on the price chart on this page. Review multi-period moves alongside volume to see how KPTI reacted to past earnings and market events.

Should I buy Karyopharm Therapeutics Inc. (KPTI) stock, at this price?

Buying Karyopharm Therapeutics Inc. (KPTI) depends on your risk tolerance, time horizon, and portfolio needs. As a Healthcare name, weigh the live quote, key stats, and valuation links on this page rather than a single price point.